Paolo Tarantino: FDA Extends Camizestrant PDUFA Date to Review Additional SERENA-6 Data

Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared a post on LinkedIn:

“Breaking: the US FDA will extend the PDUFA date to review additional data to support the approval of camizestrant based on the SERENA-6 trial.”